Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction
| Autor: | Gibson, C. Michael, Kastelein, John J.P., Phillips, Adam T., Aylward, Philip E., Yee, Megan K., Tendera, Michal, Nicholls, Stephen J., Pocock, Stuart, Goodman, Shaun G., Alexander, John H., Lincoff, A. Michael, Bode, Christoph, Duffy, Danielle, Heise, Mark, Berman, Gail, Mears, Sojaita Jenny, Tricoci, Pierluigi, Deckelbaum, Lawrence I., Steg, P. Gabriel, Ridker, Paul, Mehran, Roxana |
|---|---|
| Zdroj: | In American Heart Journal January 2021 231:121-127 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect